Endocrine Testing Market Size, Share, Growth Report 2030

Market Overview    

The global Endocrine Testing market accounted for USD 8.4 Billion in 2020 and is expected to reach USD 16.6 Billion by 2028, growing at a CAGR of 8.9% from 2021 to 2028.    

The endocrine system is a setup of glands that produce and discharge hormones which aid control several vital body utilities, inclusive of the body's capability to alteration of calories into energy which commands organs and cells. The endocrine system impacts the way our heart beats, growth of bones and tissues, also the ability to make a kid. It plays a key role in developing diabetes, growth disorders, sexual dysTest, thyroid disease and a multitude of additional hormone-related disorders.

Key players in the industry are developing advanced testing devices for the end-users at a competitive price point. Major collaborations, technologically enhanced products and regulatory approvals are other factors stimulating the market.

Request Free Sample

COVID-19 Impact Analysis:

The restrictions imposed by various nations to contain COVID had stopped the demand and supply resulting in a disruption across the whole supply chain. However, the global markets are slowly opening to their full potential and theirs a surge in demand. The market would remain bullish in upcoming year.  The significant decrease in the Global Endocrine Test market End-user in 2020 is estimated on the basis of the COVID-19 outbreak and its negative impact on the economies and industries across the globe. Various scenarios have been analyzed on the basis of inputs from various secondary sources and the current data available about the situation.  

Growth Factors

Mounting health awareness, early endocrine disorder diagnosis, and favorable government policies is predicted to inflate the growth of endocrine testing market over the ensuing years. Apart from this, exponential increase in diabetes patients and elderly & obese population is forecast to augment the endocrine testing market End-user over the forthcoming years.

Soaring technology costs, however, is projected to inhibit the progression of endocrine testing market over the next few years. Nevertheless, massive funding of R&D activities and technological innovations are expected to open new growth opportunities for the business, thereby normalizing the impact of hindrances on the endocrine testing market.

Report Scope:

Segment Analysis Preview  

Endocrine Testing market is segmented into Dehydroepiandrosterone sulfate (DHEAS),  Progesterone, Luteinizing Hormone (LH), Estradiol (E2), Human Chorionic Gonadotropin (hCG), Follicle Stimulating (FSH), Testosterone, Thyroid prolactin, Thyroid Stimulating Hormone (TSH), cortisol, insulin and Other Test. Thyroid Stimulating Hormone (TSH) is anticipated to grow owing to increasing thyroid related disorders across the globe.

On the basis of technology the market is segmented into Monoclonal & Polyclonal Antibody Technologies, Tandem Mass Spectrometry, Immunoassay, Sensors, Clinical Chemistry Technologies, and Others. Clinical Chemistry Technologies segmented is projected to grow owing to major technical advancement coupled with enhanced diagnostics demand.

On the basis of End-user Endocrine Testing is segmented into Commercial Laboratories, Home-Based Tests, Ambulatory Care Centers, Hospitals, and Other Healthcare Settings. Hospital segment is anticipated to grow owing to increasing demand of health facilities across the globe.

North America region hold the major share in the market and is likely to remain dominant throughout the forecast period. This is due to the development of innovative easy-to-operate test kits equipped with biosensors that facilitate user-friendly and cost-effective home-based diagnosis is creating a positive outlook for the market.

Request Free Sample

Key Market Players & Competitive Landscape

The major players operating in the Endocrine Testing market are Bio Rad Laboratories, DIASORIN, Hoffmann-La Roche Ltd., LabCorp, Quest Diagnostics,  Abbott Laboratories, AB Sciex, Agilent Technologies, Biomedical Technologies, and  bioMerieux SA, among others.

Request Free Sample

The global Endocrine Testing market is segmented as follows:   

By Tests

• Dehydroepiandrosterone sulfate (DHEAS)
• Progesterone
• Luteinizing Hormone (LH)
• Estradiol (E2)
• Human Chorionic Gonadotropin (hCG), Follicle Stimulating (FSH)
• Testosterone
• Thyroid prolactin
• Thyroid Stimulating Hormone (TSH), cortisol, insulin
• Other Test

By Technology

• Monoclonal & Polyclonal Antibody Technologies
• Tandem Mass Spectrometry
• Immunoassay
• Sensors
• Clinical Chemistry Technologies
• Others

By End-user

• Commercial Laboratories
• Home-Based Tests
• Ambulatory Care Centers
• Hospitals
• Other Healthcare Settings

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa